エストニア - エストニア語 - Ravimiamet

ucb pharma oy finland - levotsetirisiin - suukaudne lahus - 0,5mg 1ml 200ml 1tk

エストニア - エストニア語 - Ravimiamet

ucb pharma oy finland - tsetirisiin - õhukese polümeerikattega tablett - 10mg 90tk; 10mg 7tk; 10mg 1tk; 10mg 10tk; 10mg 5tk; 10mg 60tk; 10mg 15tk; 10mg 21tk; 10mg 45tk; 10mg 20tk

欧州連合 - エストニア語 - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - diabeetis kasutatavad ravimid - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

エストニア - エストニア語 - Ravimiamet

ideal trade links uab - levotsetirisiin - õhukese polümeerikattega tablett - 5mg 60tk; 5mg 10tk; 5mg 20tk

欧州連合 - エストニア語 - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - merkaptaamiini bitartraat - tsüstinoos - muud alimentary seedetrakti ja ainevahetust tooted, - procysbi on näidustatud tõestatud nefropaatilise tsüstinoosi raviks. tsüsteamiin vähendab tsüstiini kogunemist mõnedes rakkudes (e. leukotsüüdid, lihas- ja maksarakud) nefropaatilise tsüstinoosiga patsientidel ning kui ravi alustatakse varakult, siis viivitab see neerupuudulikkuse arengut.

欧州連合 - エストニア語 - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leukeemia, karvane rakk - antineoplastilised ained - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

エストニア - エストニア語 - Ravimiamet

ucb pharma oy finland - tsetirisiin - suukaudsed tilgad, lahus - 10mg 1ml 20ml 1tk; 10mg 1ml 10ml 1tk

エストニア - エストニア語 - Ravimiamet

ucb pharma oy finland - tsetirisiin - suukaudne lahus - 1mg 1ml 150ml 1tk; 1mg 1ml 75ml 1tk; 1mg 1ml 100ml 1tk; 1mg 1ml 200ml 1tk

エストニア - エストニア語 - Ravimiamet

lex ano uab - tsetirisiin - suukaudsed tilgad, lahus - 10mg 1ml 20ml 1tk

エストニア - エストニア語 - Ravimiamet

ideal trade links uab - tsetirisiin - õhukese polümeerikattega tablett - 10mg 10tk; 10mg 30tk